Trastuzumab Deruxtecan

證據等級: L5

預測適應症: 1 個

Trastuzumab Deruxtecan: From HER2-Targeted ADC Therapy to Drug-Induced Osteoporosis

One-Sentence Summary

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) carrying a cytotoxic topoisomerase I inhibitor payload (DXd); the original approved indication is not documented in this evidence pack. The TxGNN model predicts a possible association with drug-induced osteoporosis, but this is supported by 0 clinical trials and 0 publications — the prediction rests entirely on the model score, with no independent evidence.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (data gap — MOA and original indication fields both blank)
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	99.31%
Evidence Level	L5
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in structured form (original_moa = data gap). However, the evidence pack's own rationale text identifies trastuzumab deruxtecan as a HER2-targeted antibody-drug conjugate whose payload, DXd, is a topoisomerase I inhibitor — a systemic cytotoxic chemotherapy agent, not a bone-protective agent.

Clinically, cytotoxic chemotherapy and HER2-directed endocrine-adjacent regimens (e.g., aromatase inhibition, ovarian suppression in HER2+ breast cancer) are well-recognized causes of drug-induced bone loss, not treatments for it. The predicted link therefore runs in the opposite direction from established pharmacology: the drug is mechanistically more plausible as a risk factor for osteoporosis than as a therapy for it.

Given this, the prediction should be treated as a likely false positive of the data-driven TxGNN model rather than a biologically grounded repurposing hypothesis. No mechanistic, trial, or literature evidence currently supports pursuing this indication.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Norway Market Information

Trastuzumab deruxtecan is not currently marketed in Norway; no authorizations are on record.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (HER2-directed ADC) with conventional cytotoxic payload (DXd, topoisomerase I inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Must follow cytotoxic/ADC drug handling regulations

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is unsupported by any clinical trial or literature evidence and is mechanistically implausible — the drug's known cytotoxic ADC profile is more consistent with causing bone loss than treating osteoporosis. Combined with blocking data gaps in MOA and TFDA safety labeling, there is no basis to advance this candidate.

To proceed, the following is needed:

Confirmed original approved indication and MOA data (currently missing from evidence pack)
TFDA/manufacturer package insert (warnings, contraindications) — currently a blocking data gap
Independent mechanistic or preclinical evidence explaining a plausible bone-protective effect, if any exists, before further evaluation
Re-review after data gaps DG001/DG002 are remediated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.